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Abstract
Background: Pre-eclampsia/eclampsia is a common vascular pregnancy disorder associated with high maternal
and infant mortality and morbidity worldwide. The role of Activin A and more recently type 2 Activin A receptor
(ACVR2A) in the pathogenesis of pre-eclampsia has been the subject of genetic and biochemical research with
controversial results.
Findings: We genotyped a candidate pre-eclampsia-associated single nucleotide polymorphism rs1424954 in
ACVR2A in three independent study populations of Finnish pre-eclamptic (total N = 485) and non-pre-eclamptic
(total N = 449) women using pre-designed TaqMan allele discrimination assay and polymerase chain reaction. The
possible association of the alleles and genotypes of interest with pre-eclampsia was evaluated using the chi-square
test and logistic regression analysis. We found no association of rs1424954 to pre-eclampsia in Finnish patients.
Conclusions: rs1424954 was not associated to pre-eclampsia in the Finnish study population. We hypothesise that
while the gene associates to pre-eclampsia worldwide, the causative polymorphism in ACVR2A may be unique in
genetically differing populations. Further research is needed to characterise the haplotype structure of ACVR2A in
order for the causative genetic variant to be identified.
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Background
Pre-eclampsia (PE) is a serious disorder of human preg-
nancy characterised by new-onset hypertension and pro-
teinuria after 20 weeks of gestation. PE may lead to
multi-organ dysfunction and rarely, to a life-threatening
convulsive condition, eclampsia (E). PE affects 3-5% of
pregnancies worldwide and occurs in all ethnic groups.
It is considered a feto-maternal problem, immunology-
related poor placentation playing a role in the etiology
[1], The development and the progression of the disease
are unpredictable, and no effective therapy is currently
available apart from the delivery of the placenta [2]. In
the mother, PE is associated with an increased risk of
cardiovascular disease (CVD) in later life [2,3].
The cell signaling protein activin A is a dimeric mem-
ber of the transforming growth factor-b (TGF-b) super-
family of signaling proteins. The role of TGF-b proteins
has previously been described in various cellular pro-
cesses required for reproductive function including reg-
ulation of cell proliferation, differentiation and apoptosis
[4,5]. Activin A plays a role in endothelial regulation
and maternal endovascular inflammatory response [6-8].
Activin receptors type I and type II, hereafter ACVR1
and ACVR2, are barrel like transmembrane receptor
proteins. Activin A binds with ACVR2 which associates
with and phosphorylates ACVR1. Activin receptors are
expressed in the endometrium, placental tissue, vascular
endothelial cells and trophoblasts from early on in preg-
nancy [9,10]. ACVR2 is coded by the activin receptor
gene ACVR2A on chromosome 2q22 [11].
Genetic factors are a major contributor to susceptibil-
ity to PE [12]. The genetic risk of PE is considered to be
complex, and the strongest evidence to date exists for
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maternal risk [13]. Linkage studies in Australian, New
Zealand and Icelandic pedigrees have demonstrated a
PE susceptibility locus on chromosome 2q22-23 [14,15].
ACVR2A has been described as a putative candidate
gene [16].
PE/E has been associated with elevated maternal serum
levels of activin A in several studies [17,18]. It has been
suggested that a defective expression of ACVR2A may
influence activin A concentrations and thereby alter the
processes of decidualisation, trophoblast invasion and
remodelling of the spiral arteries [16]. A dysregulated
receptor expression, i.e. downregulated ACVR2A expres-
sion, may cause elevated activin A serum levels. Hypote-
tically, this might be a shared mechanism between CVD
and PE/E, leading to an imbalance of anti-inflammatory
and inflammatory responses [19].
Moses and al. [16] found an association between PE
and a single nucleotide polymorphism (SNP)
(rs1424954), located approximately 1800 bp upstream of
the transcriptional start site in the ACVR2A gene. To
replicate this first finding, we analysed whether the A -
> G polymorphism on this ACVR2A gene site would be
associated with PE in a Finnish study population.
Methods
The SNP rs1424954 was genotyped in a total of 485 Fin-
nish women with prior PE and 449 control subjects
from three different study populations described below.
Both primiparous and multiparous women were
included in the study. In the absence of patient identi-
fiers, Data sets 1, 2 and 3 were cross-checked for a com-
bination of age, body mass index (BMI), and relative
birth weight to exclude the possibility of double-recruit-
ment. All subjects provided a written informed consent,
and all study protocols were approved by the appropri-
ate local Ethical Committees. In addition, the approval
of the Finnish Ministry of Social Affairs and Health was
obtained for the population-based study (Data set 1).
The diagnostic criteria of PE used are defined below
separately for each study. Systolic blood pressure ≥ 160
mmHg and/or diastolic blood pressure ≥ 110 mmHg
was classified as severe PE. The criteria for severe PE
used in this study do not include the severity of protei-
nuria as quantitative measurements of proteinuria were
not available for all cases.
Pre-pregnancy weight and height were obtained from
the antenatal care records where they are in most cases
recorded as reported by the mother at the first mater-
nity clinic visit, usually before 12 weeks of gestation.
BMI was defined as the pre-pregnancy weight in kilo-
grams divided by height in meters squared (kg/m2).
Small-for-gestational age (SGA) was defined as relative
birth weight under -2.0 SD units (Z-score) according to
Finnish standards [20].
Data Set 1: Finnish population-based preeclampsia study
The cases and controls for the population-based data set
were identified by combining two national registers [21].
In Finland, pregnant women are registered in the
National Register of Blood Group and Blood Group
Antibodies of Pregnant Women at the Finnish Red
Cross Blood Service, from which 100,000 consecutive
pregnant women were identified during 1997-1998. Of
these, 1084 had an International Classification of Dis-
eases (ICD-10) code for PE or eclampsia in the National
Hospital Discharge Register maintained by the National
Research and Development Centre for Welfare and
Health. First 665 women with PE diagnosis were invited
to the study and 411 (62%) participated. After checking
the case records and excluding multiple pregnancies,
226 cases with singleton pregnancies fulfilled the criteria
for PE. In addition to PE patients, a random sample of
women without pregnancy complications (n = 1930)
were invited to the study and 843 (44%) participated. Of
these, 346 women with singleton full-term pregnancies
without hypertensive complications, matched as closely
as possible with the cases for the province of residence,
parity, and maternal age, served as controls in this
study. All participants were of Finnish ethnic origin,
gave blood samples for the study, and filled out ques-
tionnaires to supplement the data obtained from medi-
cal records.
PE was defined as systolic blood pressure ≥ 140
mmHg and diastolic blood pressure ≥ 90 mmHg with
new-onset proteinuria (0.3 g/l or ≥ 0.5 g/24 h or dip-
stick ≥ + representing values ≥ 0.3 g/l) after 20 weeks of
gestation in a previously normotensive woman (slightly
modified from ACOG criteria) [21,22]. The highest
blood pressure values were recorded.
Data Set 2: Southern Finland preeclampsia study
Using the discharge records, we identified women who
had developed severe PE and given birth in Helsinki
University Central Hospital between January 1988 and
April 1998 [23]. Patients with multiple pregnancies were
excluded. Blood samples were collected between January
1997 and April 1998 after the index pregnancy. During
the same period, blood samples were collected from
control subjects with singleton deliveries in the same
hospital after uncomplicated pregnancies. In total, 129
pre-eclamptic women and 103 normotensive healthy
controls with no pregnancy complications were
recruited. Twenty-five women were recruited as multi-
paras in the pre-eclamptic group. Ten women (40%) had
a previous pre-eclamptic pregnancy and two women
(8%) had a previous hypertensive pregnancy. Among the
PE cases, 102 women had a systolic blood pressure ≥
160 mmHg and/or a diastolic blood pressure ≥ 110 and
88 had proteinuria of at least 2 g per 24-h urine
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collection. All subjects were of Finnish ethnic origin,
lived in southern Finland and had been healthy before
their first pregnancy, without evidence of renal or auto-
immune diseases. At 12 weeks postpartum, all women
were normotensive and proteinuria had disappeared.
The diagnostic criteria of PE used were systolic blood
pressure ≥ 140 mmHg and diastolic blood pressure ≥ 90
mmHg with new-onset proteinuria (≥ 0.3 g/24 h) after
20 weeks of gestation in a previously normotensive
woman [23]. The blood pressure was confirmed by two
measurements taken at least 6 h apart.
Data Set 3: Eastern Finland preeclampsia study
The samples of this data set were collected retrospec-
tively from women with prior PE when primiparous
who delivered at Kuopio University Hospital between
January 1994 and December 1998 [24]. PE patients were
identified from the Birth Registry of the City of Kuopio,
contacted by telephone and asked to participate in the
study and sign a consent form. Patients with multiple
pregnancies were excluded. In total, samples obtained
from 130 women with prior PE in a singleton pregnancy
were analysed.
In this study, PE was defined as the development of
hypertension and new-onset proteinuria (≥ 300 mg of
urinary protein per 24 h). Hypertension was defined as
≥ 140 mmHg systolic and/or ≥ 90 mmHg diastolic pres-
sure, when measured on two consecutive occasions at
least 24 h apart [25]. Women with essential hyperten-
sion were excluded from the study.
SNP Genotyping
DNA was extracted using standard laboratory protocols.
The ACVR2A SNP (rs1424954) was genotyped using an
ABI TaqMan® Pre-Designed SNP Genotyping Assay
(Applied Biosystems, Carlsbad, CA).
Polymerase chain reaction (PCR) amplification was
carried out according to the manufacturer’s instructions.
An ABI 7500 real-time thermocycler (Applied Biosys-
tems, Foster City, CA) was used to perform plate read-
ing. Automated allele calling was performed by allelic
discrimination plots using Applied Biosystems 7500/
7500fast Real-Time PCR Software v.2.0 (Applied Biosys-
tems, Carlsbad, CA).
Statistical analyses
The Hardy-Weinberg Equilibrium Calculator of the
Genetic Online Encyclopedia was used to test for devia-
tions in genotype distributions from the Hardy-Wein-
berg equilibrium [25]. We used Genetic Power
Calculator to evaluate our ability to detect association to
marker rs1424954 (http://pngu.mgh.harvard.edu/~pur-
cell/gpc/) assuming a PE prevalence of 3%, proposed
high risk allele (G) frequency of 0.6 and genotypic rela-
tive risk of 1.1 for GA and 1.6 for GG. With these
assumptions, a sample size of 422 PE cases was esti-
mated to result in a power > 0.8443 when a < 0.05.
Differences in the background characteristics between
the cases and controls were analysed using the Student’s
t-test or the Mann-Whitney test (continuous variables),
and the Chi-square test or the Fisher’s exact test (fre-
quencies for discrete variables). Allele frequencies were
calculated directly from the genotype data. Differences
in the frequencies of genotypes and alleles among the
multiparous and the primiparous PE cases and controls
were analysed using the Chi-square test. We also tested
the genotypes containing the proposed high risk allele
(G), GG + AG, against the AA genotype. Logistic regres-
sion analysis was used to test the association of the
sequence variant studied with the delivery of an SGA
infant. P-value < 0.05 was considered as statistically sig-
nificant in all analyses. The statistical software used was
PASW Statistics 18.0 and Prism for Windows, version
4.03, GraphPad Software Inc, La Jolla, CA, USA.
Results
The clinical characteristics of the study population are
presented in Table 1. There was no significant difference
in the mean age of PE cases and controls. The cases had
a higher mean BMI than the controls, delivered earlier
and their infants had a lower birth weight. Pre-gesta-
tional and gestational diabetes were slightly more com-
mon in the primiparous PE cases than in the
primiparous control women.
Among the PE patients, 53.7% delivered before 37
weeks of gestation, whereas among the controls the rate
of preterm delivery was 0.7% (p < 0.001). SGA babies
were more common among the PE patients (28.5%)
compared with the controls (0.4%) (p < 0.001). Out of
all PE patients, 62% had severe PE.
We did not find any significant differences between
the PE cases and controls regarding the genotype or
allele frequencies of the SNP rs1424954 in the primipar-
ous, multiparous or combined samples (Table 2). No
differences in the frequency of PE were found between
the subjects having the proposed risk allele G (GG and
AG genotypes), compared with those homozygous for
the A-allele (p = 0.882). In logistic regression analysis,
when using the AA genotype as a reference, the odds
ratio (OR) for PE was 0.99 (95%CI:0.65,1.52) for the
subjects with the GG genotype and 1.07 (95%CI:0.70-
1.63) for those with the AG genotype, but the results
were not statistically significant.
There were no differences in the genotype (p = 0.570)
or allele (p = 0.414) frequencies of interest between the
women who delivered an SGA infant and those with a
non-SGA baby. The GG or the AG genotypes were not
associated with the delivery of an SGA infant (OR for
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GG: 0.93 (95%CI: 0.50,1.72), OR for AG: 1.15 (0.62,2.11),
AA = reference).
Discussion
In this replication study, we could not confirm the asso-
ciation of the candidate SNP rs1424954 to PE. The role
of ACVR2A in PE has been the subject of several inves-
tigations in recent years. The gene was originally identi-
fied as a strong candidate by Moses et al. [16] who also
described the association of rs1424954 to PE in 34 PE
families of Australian and New Zealand origin. However,
this finding failed to replicate in a larger cohort of 74
Australia/New Zealand families with a history of PE,
possibly due to the greater genetic heterogeneity of the
larger sample size [26]. Roten et al. [27] experienced
technical difficulties with the replication of rs1424954 in
a Norwegian retrospective population-based cohort, but
were still able to indicate a nominal association of the
ACVR2A gene with PE. Since the original finding of an
association to rs1424954, other SNPs have been sug-
gested [26,27]. However, due to inconclusive results we
selected to search for the association of the rs1424954
to PE in a group of Finnish PE patients with severe pla-
cental implications as indicated by the high incidence of
preterm deliveries.
The PE cases in our study met strict diagnostic cri-
teria PE in an attempt to avoid the challenges posed by
genetic heterogeneity as described by Fitzpatrick et al.
[26]. Due to the relative historic isolation, the Finnish
population bears characteristics of a founder population
with the potential of reduced genetic heterogeneity [28].
However, the risk of population stratification brought
Table 1 Clinical characteristics of Finnish pre-eclampsia (PE) patients and control subjects (mean and standard
deviation SD) combined from Finnish population based Data set (Data set 1), Southern Finland PE Data set (Data set
2) and Eastern Finland PE Data Set (Data set 3)
Pre-eclampsia Controls
Primiparous (n =
321)
Multiparous (n =
164)
Primiparous (n =
264)
Multiparous (n =
185)
Primiparous Multiparous
N Mean SD N Mean SD N Mean SD N Mean SD p* p*
Age (years) 321 27.7 5.4 164 31.8 5.2 264 27.6 4.7 185 31.0 4.9 0.374 0.177
BMI (kg/m2) 302 23.8 4.5 162 24.6 4.4 264 22.2 3.1 185 23.2 3.7 < 0.001 0.002
Systolic BP (mmHg) 315 167.0 18.4 154 169.6 17.1 80 118.6 9.0 22 119.1 11.9 < 0.001 < 0.001
Diastolic BP (mmHg) 316 105.7 10.1 154 105.1 10.4 80 73.6 7.8 22 72.2 8.9 < 0.001 < 0.001
Birth weight (g) 320 2399.9 934.6 162 2382.6 863.2 264 3537.8 404.0 185 3635.0 412.8 < 0.001 < 0.001
Relative birth weight (SD) 311 -1.4 1.3 160 -1.2 1.3 262 -0.2 0.8 183 0.0 0.8 < 0.001 < 0.001
Gestational age at birth (weeks) 315 35.7 3.9 164 35.5 3.5 264 39.9 1.5 185 40.0 1.2 < 0.001 < 0.001
N % N % N % N % p** p**
Gestational diabetes 16 5.4 7 4.3 5 1.9 12 6.5 0.046 0.362
Pre-gestational diabetes 8 2.7 5 3.1 1 0,0 1 0.5 0.046 0.103
* Student’s t-test or Mann-Whitney test. ** Chi-square test or Fisher’s exact test
Table 2 ACVR2A genotypes and allele counts among Finnish pre-eclampsia (PE) patients and control subjects
combined from Finnish population based Data set (Data set 1), Southern Finland PE Data set (Data set 2) and Eastern
Finland PE Data Set (Data set 3)
Pre-eclampsia Controls p**
Primiparous
(n = 321)
Multiparous
(n = 164)
Combined (n
= 485)
Primiparous
(n = 264)
Multiparous
(n = 185)
Combined
(n = 449)
Primiparous Multiparous Combined
Genotypes
GG 134 67 201 108 87 195
AG 148 70 218 121 76 197
AA 32 24 56 33 21 54 0.468 0.660 0.871
N/A* 7 3 10 2 1 3
Alleles (Frequency)
G 416 204 620 337 250 587
A 212 118 330 187 118 305 0.493 0.205 0.806
* Genotyping failed ** Chi-square test
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about by inclusion of the Eastern Finland case cohort
exists [28]. One weakness of our study is that it com-
bines three retrospectively collected data sets in which
the extent of coded information available varies. There-
fore, for example, we did not have access to data on the
status of previous pregnancies of multiparous women.
The above-mentioned studies have supported the role
of ACVR2A in PE, although conclusive evidence is still
lacking. Fitzpatrick et al. identified nine new SNPs in
the ACVR2A region [26]. This enabled the description
of defined Linkage Disequilibrium (LD) patterns which
were subsequently replicated in the Norwegian popula-
tion [26,27]. We hypothesise that while the haplotypes
in the region are conserved, the causative variant may
vary among populations with differing genetic back-
grounds. Indeed, the SNP rs1424954 lies more than 1.5
kb upstream of the ACVR2A gene. We postulate that a
regulatory region with population-specific polymorph-
isms in this locus might explain the previously reported
association to PE [16]. It is possible that the causative
variant lies among one of the other haploblock struc-
tures previously described in the ACVR2A gene [27].
Furthermore, we hypothesise that the predisposing
genetic effect of ACVR2A in PE is, in fact, a collection
of associated alleles rendering the effect of individual
SNPs undetectable in even cohorts with the strictest
inclusion criteria.
Conclusions
The locus 2q22-23, where ACVR2A is located, has been
indicated as a susceptibility locus for PE in several
population cohorts with different ancestral background.
The functional description of the gene continues to
attract PE investigators towards ACVR2A. The first
reported candidate SNP from previous studies,
rs1424954, was not replicated in Finnish patients with
PE. Thus far a common causative variant has not been
identified. Further studies in the field are important to
increase the understanding of the role of ACVR2A in
the pathogenesis of PE
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